Equity Overview
Price & Market Data
Price: $0.0₃1
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $3,213
Volume: 0
Details
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.